MCID: SLV026
MIFTS: 56

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Salivary Gland Carcinoma

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 38 56 44 15
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Malignant Neoplasm of Salivary Gland 12
Major Salivary Gland Carcinoma 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 38 H01508
ICD9CM 36 142.8
ICD10 34 C08
UMLS 74 C0153362

Summaries for Salivary Gland Carcinoma

MedlinePlus : 44 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and salivary gland cancer, adult. An important gene associated with Salivary Gland Carcinoma is MAML2 (Mastermind Like Transcriptional Coactivator 2), and among its related pathways/superpathways are Notch signaling pathway and PI3K-Akt signaling pathway. The drugs Iodine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Related Diseases for Salivary Gland Carcinoma

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 31.8 CRTC1 CRTC3 EGFR MAML2
2 salivary gland cancer, adult 12.6
3 salivary gland cancer, childhood 12.3
4 adenoid cystic carcinoma 11.6
5 brooke-spiegler syndrome 11.3
6 sublingual gland cancer 11.2
7 parotid gland cancer 11.2
8 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
9 deafness, autosomal recessive 39 10.4 HGF MET
10 infiltrating angiolipoma 10.4 CDKN2A MDM2
11 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
12 deafness, autosomal recessive 97 10.4 HGF MET
13 acral lentiginous melanoma 10.3 CDKN2A KIT MET
14 small cell carcinoma 10.3 CDKN2A EGFR KIT
15 chordoma 10.3 CDKN2A EGFR MET
16 fibrosarcoma of bone 10.3 CDKN2A KIT MDM2
17 doxorubicin induced cardiomyopathy 10.3 EGFR HGF MET
18 endometrial squamous cell carcinoma 10.3 CDKN2A HGF MET
19 familial renal papillary carcinoma 10.3 EGFR HGF MET
20 grade iii astrocytoma 10.3 CDKN2A EGFR MDM2
21 central nervous system melanocytic neoplasm 10.3 CDKN2A HGF KIT
22 spinal chordoma 10.3 EGFR HGF MET
23 nervous system cancer 10.3 CDKN2A EGFR MDM2
24 conventional fibrosarcoma 10.3 KIT MDM2
25 central nervous system cancer 10.3 CDKN2A EGFR SOX2
26 cellular schwannoma 10.3 CDKN2A MDM2 SOX2
27 lacrimal gland mucoepidermoid carcinoma 10.3 CRTC1 MAML2
28 ocular cancer 10.3 CDKN2A MDM2 SOX2
29 respiratory system cancer 10.3 CDKN2A EGFR MET
30 li-fraumeni syndrome 10.3 CDKN2A EGFR MDM2
31 sarcoma, synovial 10.3 KIT MDM2 MET
32 adenoid basal cell carcinoma 10.3 CDKN2A KIT
33 lacrimal system cancer 10.3 MAML2 NFIB
34 large cell medulloblastoma 10.3 HGF MET
35 cutaneous mucoepidermoid carcinoma 10.3 CRTC1 MAML2
36 spindle cell synovial sarcoma 10.3 HGF ISL1 MET
37 breast mucoepidermoid carcinoma 10.2 CRTC1 MAML2
38 malignant peripheral nerve sheath tumor 10.2 CDKN2A EGFR KIT MDM2
39 gastrointestinal system cancer 10.2 CDKN2A EGFR KIT MET
40 supratentorial cancer 10.2 CDKN2A EGFR MDM2 SOX2
41 cerebrum cancer 10.2 CDKN2A EGFR MDM2 SOX2
42 clear cell hidradenoma 10.2 CRTC1 MAML2
43 adamantinoma of long bones 10.2 CDKN2A EGFR MDM2 SOX2
44 glioblastoma multiforme 10.2 CDKN2A EGFR MDM2 MET
45 pharynx cancer 10.2 CDKN2A EGFR KIT NFIB
46 cholangiocarcinoma 10.2 CDKN2A EGFR HGF MET
47 atypical lipomatous tumor 10.2 CDKN2A MDM2
48 renal cell carcinoma, nonpapillary 10.1 EGFR HGF KIT MET
49 gastrointestinal system disease 10.1 CDKN2A EGFR KIT
50 patulous eustachian tube 10.1

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma

Symptoms & Phenotypes for Salivary Gland Carcinoma

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 EGFR
2 Decreased viability GR00221-A-1 9.66 CDKN2A CYLD EGFR HGF KIT SOX2
3 Decreased viability GR00221-A-2 9.66 CYLD HGF
4 Decreased viability GR00221-A-3 9.66 CDKN2A
5 Decreased viability GR00221-A-4 9.66 CDKN2A EGFR HGF SOX2
6 Decreased viability GR00301-A 9.66 CYLD KIT
7 Decreased viability GR00402-S-2 9.66 CDKN2A CYLD EGFR HGF KIT SOX2

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

47 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 ALKBH1 CDKN2A CRTC1 CRTC3 CYLD EGFR
2 cellular MP:0005384 10.4 ALKBH1 ALKBH3 CDKN2A CRTC3 CYLD EGFR
3 homeostasis/metabolism MP:0005376 10.37 ALKBH3 CDKN2A CRTC1 CRTC3 CYLD EGFR
4 endocrine/exocrine gland MP:0005379 10.33 ALKBH1 CDKN2A CRTC1 CYLD EGFR ISL1
5 behavior/neurological MP:0005386 10.3 CDKN2A CRTC1 CYLD ISL1 KIT MC3R
6 mortality/aging MP:0010768 10.29 ALKBH1 ALKBH3 CDKN2A CRTC3 CYLD EGFR
7 embryo MP:0005380 10.26 ALKBH1 CDKN2A EGFR HGF ISL1 KIT
8 cardiovascular system MP:0005385 10.24 ALKBH1 CDKN2A EGFR HGF ISL1 KIT
9 digestive/alimentary MP:0005381 10.22 CDKN2A CYLD EGFR ISL1 KIT MDM2
10 limbs/digits/tail MP:0005371 10.21 ALKBH1 CRTC3 CYLD EGFR ISL1 KIT
11 craniofacial MP:0005382 10.18 ALKBH1 EGFR ISL1 KIT MDM2 MET
12 muscle MP:0005369 10.06 CDKN2A CRTC3 EGFR ISL1 KIT MDM2
13 liver/biliary system MP:0005370 10.04 CDKN2A CRTC3 EGFR HGF KIT MDM2
14 neoplasm MP:0002006 10.03 CDKN2A CYLD EGFR ISL1 KIT MDM2
15 no phenotypic analysis MP:0003012 10.01 CDKN2A EGFR HGF ISL1 KIT MDM2
16 normal MP:0002873 9.97 ALKBH3 CYLD EGFR ISL1 KIT MDM2
17 reproductive system MP:0005389 9.91 ALKBH1 CDKN2A CRTC1 EGFR ISL1 KIT
18 pigmentation MP:0001186 9.72 CDKN2A EGFR KIT MDM2 SOX2
19 respiratory system MP:0005388 9.7 CDKN2A CYLD EGFR KIT MET NFIB
20 skeleton MP:0005390 9.65 ALKBH1 CDKN2A CRTC3 EGFR ISL1 KIT
21 vision/eye MP:0005391 9.32 ALKBH1 CDKN2A EGFR ISL1 KIT MET

Drugs & Therapeutics for Salivary Gland Carcinoma

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
6
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
10
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
11
Promethazine Approved, Investigational Phase 3 60-87-7 4927
12
leucovorin Approved Phase 3,Phase 1 58-05-9 143 6006
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
15
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
16
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 59-30-3 6037
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 cadexomer iodine Phase 3
20 Pharmaceutical Solutions Phase 3,Phase 2
21 Peripheral Nervous System Agents Phase 3,Phase 2
22 Neurotransmitter Agents Phase 3,Phase 2
23 Autonomic Agents Phase 3,Phase 2
24 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
25 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1
27 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
28 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Early Phase 1
29 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2,Not Applicable
30 Dermatologic Agents Phase 3,Phase 2
31 Antimetabolites Phase 3,Phase 1,Phase 2
32 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
33 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Not Applicable
35 Immunoglobulins Phase 3,Phase 1,Phase 2
36 Antineoplastic Agents, Immunological Phase 3,Phase 1,Phase 2
37 Antibodies Phase 3,Phase 1,Phase 2
38 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
39 Muscarinic Agonists Phase 3,Phase 2
40 Cholinergic Agents Phase 3,Phase 2
41 Narcotics Phase 3
42 Adjuvants, Anesthesia Phase 3
43 Analgesics Phase 3,Phase 2
44 Anesthetics, Intravenous Phase 3
45 Anesthetics, General Phase 3
46 Anesthetics Phase 3
47 Analgesics, Opioid Phase 3
48 Central Nervous System Depressants Phase 3
49 Histamine Antagonists Phase 3
50 Psychotropic Drugs Phase 3

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
2 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
3 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
8 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
9 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
11 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
12 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
13 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
14 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2 Sorafenib
15 Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck Unknown status NCT02558387 Phase 2 BIBF1120
16 Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers Unknown status NCT02867852 Phase 2 Abiraterone acetate
17 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
18 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
19 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
20 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
21 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
22 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
23 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
24 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2 Gefitinib
25 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
26 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer Completed NCT01613768 Phase 2 eribulin mesylate
27 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
28 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2 Trastuzumab
29 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
30 Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Completed NCT00002632 Phase 2 paclitaxel
31 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
32 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
33 Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma Completed NCT00228488 Phase 2 Gefitinib
34 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
35 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
36 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed NCT01175980 Phase 2 Vorinostat
37 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
38 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
39 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
40 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Completed NCT02123511 Phase 2 acetylcysteine
41 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
42 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
43 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
44 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
45 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
46 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
47 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
48 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
49 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
50 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride

Search NIH Clinical Center for Salivary Gland Carcinoma

Genetic Tests for Salivary Gland Carcinoma

Anatomical Context for Salivary Gland Carcinoma

MalaCards organs/tissues related to Salivary Gland Carcinoma:

42
Salivary Gland, Testes, Brain, Lymph Node, Liver, Thyroid, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

20
The Salivary Gl

Publications for Salivary Gland Carcinoma

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 262)
# Title Authors Year
1
External beam radiotherapy for the treatment of feline salivary gland carcinoma: six new cases and a review of the literature. ( 29767566 )
2019
2
ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma. ( 30374620 )
2019
3
The limited role of elective neck dissection in patients with cN0 salivary gland carcinoma. ( 30528947 )
2019
4
Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review. ( 30649610 )
2019
5
High metastatic node number, not extranodal extension, as a node-related prognosticator in surgically treated patients with nodal metastatic salivary gland carcinoma. ( 30652371 )
2019
6
New approaches in salivary gland carcinoma. ( 30844885 )
2019
7
Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology. ( 30932974 )
2019
8
Salivary gland carcinoma in Shanghai (2003-2012): an epidemiological study of incidence, site and pathology. ( 30975127 )
2019
9
Secretory Carcinoma of the Parotid: Making the Correct Diagnosis of a Rare Salivary Gland Carcinoma When Molecular Biology Testing Is Not Available. ( 31007960 )
2019
10
Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis. ( 31014362 )
2019
11
Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. ( 31028207 )
2019
12
Diplopia: a unique presentation of recurrence of a salivary gland carcinoma. ( 31061174 )
2019
13
Up-front F18-FDG PET/CT in suspected salivary gland carcinoma. ( 31102059 )
2019
14
Impact of tumour profiling on clinical trials in salivary gland cancer. ( 30102009 )
2019
15
Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats. ( 30338701 )
2019
16
Survival and characteristics of pediatric salivary gland cancer: A systematic review and meta-analysis. ( 30378272 )
2019
17
The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. ( 30472214 )
2019
18
Impact of treating facilities' type and volume in patients with major salivary gland cancer. ( 30698823 )
2019
19
Uptake of 18F-Fluorodeoxyglucose in Major Salivary Gland Cancer Predicts Survival Adjusting for Pathological Stage. ( 30711993 )
2019
20
Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. ( 30905082 )
2019
21
Correlation of apparent diffusion coefficient with histopathological parameters of salivary gland cancer. ( 30975578 )
2019
22
Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: a multicenter retrospective analysis. ( 28936637 )
2018
23
Second primary cancer after major salivary gland carcinoma. ( 28960648 )
2018
24
Minor Salivary Gland Carcinoma of the Oropharynx: A Population-Based Analysis of 1426 Patients. ( 28971745 )
2018
25
Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma. ( 29151106 )
2018
26
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. ( 29211833 )
2018
27
Combined androgen blockade for salivary gland carcinoma. ( 29233558 )
2018
28
Retraction: Genome-wide association study identifies common genetic variants associated with salivary gland carcinoma and its subtypes by Xu L, Tang H, Chen DW, El-Naggar AK, Wei P, Sturgis EM. ( 29406587 )
2018
29
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. ( 29462123 )
2018
30
Health-related quality of life in patients with major salivary gland carcinoma. ( 29478078 )
2018
31
Prognostic significance and optimal candidates of primary tumor resection in major salivary gland carcinoma patients with distant metastases at initial presentation: A population-based study. ( 29496064 )
2018
32
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. ( 29863801 )
2018
33
Retraction: Genetic Variants in DNA Double-Strand Break Repair Genes and Risk of Salivary Gland Carcinoma: A Case-Control Study. ( 29928030 )
2018
34
Salivary gland carcinoma: Prediction of cancer death risk based on apparent diffusion coefficient histogram profiles. ( 29975742 )
2018
35
Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. ( 30050326 )
2018
36
Pretreatment Primary Tumor and Nodal SUVmax Values on 18F-FDG PET/CT Images Predict Prognosis in Patients With Salivary Gland Carcinoma. ( 30273205 )
2018
37
Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. ( 30293119 )
2018
38
Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study. ( 28881386 )
2018
39
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. ( 29044862 )
2018
40
Treatment Times in Salivary Gland Cancer: National Patterns and Association with Survival. ( 29460669 )
2018
41
Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. ( 29555661 )
2018
42
Development of a novel salivary gland cancer lymph node staging system. ( 29742277 )
2018
43
AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report. ( 29873033 )
2018
44
Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer. ( 29925355 )
2018
45
Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer. ( 29949051 )
2018
46
Androgen deprivation therapy for metastatic salivary gland cancer. ( 30127038 )
2018
47
Insurance Status and Survival of Patients with Salivary Gland Cancer. ( 30324868 )
2018
48
Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer. ( 30558663 )
2018
49
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
50
Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma. ( 27846763 )
2017

Variations for Salivary Gland Carcinoma

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 376)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6845145 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 0
2 COSM6979379 TSHR salivary gland,major,carcinoma,NS c.1376C>T p.A459V 14:81143434-81143434 0
3 COSM6983845 TSC2 salivary gland,major,carcinoma,NS c.2276G>A p.R759K 16:2072904-2072904 0
4 COSM6939530 TSC2 salivary gland,major,carcinoma,NS c.2402C>T p.A801V 16:2074246-2074246 0
5 COSM6939527 TSC1 salivary gland,major,carcinoma,NS c.2684T>A p.V895D 9:132897552-132897552 0
6 COSM43878 TP53 salivary gland,major,carcinoma,NS c.427G>A p.V143M 17:7675185-7675185 0
7 COSM10777 TP53 salivary gland,major,carcinoma,NS c.715A>G p.N239D 17:7674248-7674248 0
8 COSM10662 TP53 salivary gland,major,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
9 COSM10905 TP53 salivary gland,major,carcinoma,NS c.451C>T p.P151S 17:7675161-7675161 0
10 COSM43951 TP53 salivary gland,major,carcinoma,NS c.643A>G p.S215G 17:7674888-7674888 0
11 COSM10659 TP53 salivary gland,major,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10705 TP53 salivary gland,major,carcinoma,NS c.586C>T p.R196* 17:7674945-7674945 0
13 COSM10648 TP53 salivary gland,major,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 0
14 COSM43931 TP53 salivary gland,major,carcinoma,NS c.523C>A p.R175S 17:7675089-7675089 0
15 COSM11354 TP53 salivary gland,major,carcinoma,NS c.991C>T p.Q331* 17:7673537-7673537 0
16 COSM43680 TP53 salivary gland,major,carcinoma,NS c.523C>T p.R175C 17:7675089-7675089 0
17 COSM44119 TP53 salivary gland,major,carcinoma,NS c.483C>T p.A161A 17:7675129-7675129 0
18 COSM10758 TP53 salivary gland,major,carcinoma,NS c.659A>G p.Y220C 17:7674872-7674872 0
19 COSM10786 TP53 salivary gland,major,carcinoma,NS c.949C>T p.Q317* 17:7673579-7673579 0
20 COSM307275 TP53 salivary gland,major,carcinoma,NS c.96+1G>T p.? 17:7676381-7676381 0
21 COSM6930930 TENT5C salivary gland,major,carcinoma,NS c.702G>C p.K234N 1:117623570-117623570 0
22 COSM6983859 TCF3 salivary gland,major,carcinoma,NS c.173C>T p.S58F 19:1632378-1632378 0
23 COSM6983856 SUZ12 salivary gland,major,carcinoma,NS c.766C>T p.R256C 17:31975656-31975656 0
24 COSM6951891 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 0
25 COSM6951889 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 0
26 COSM6939534 STAG2 salivary gland,major,carcinoma,NS c.2405T>G p.I802S 23:124071195-124071195 0
27 COSM6920823 STAG2 salivary gland,major,carcinoma,NS c.1808G>A p.G603E 23:124063192-124063192 0
28 COSM6924542 SPEN salivary gland,major,carcinoma,NS c.1648C>T p.R550C 1:15920882-15920882 0
29 COSM6939532 SOX9 salivary gland,major,carcinoma,NS c.1457T>A p.V486D 17:72124314-72124314 0
30 COSM6983831 SOX17 salivary gland,major,carcinoma,NS c.1181C>T p.A394V 8:54459931-54459931 0
31 COSM6939526 SMO salivary gland,major,carcinoma,NS c.385G>C p.V129L 7:129203437-129203437 0
32 COSM2769709 SMO salivary gland,major,carcinoma,NS c.1513C>T p.P505S 7:129210409-129210409 0
33 COSM1226761 SMARCA4 salivary gland,major,carcinoma,NS c.3967C>T p.R1323C 19:11034929-11034929 0
34 COSM6941870 SMARCA4 salivary gland,major,carcinoma,NS c.848C>G p.P283R 19:10986992-10986992 0
35 COSM6951921 SH2B3 salivary gland,major,carcinoma,NS c.1226G>A p.G409E 12:111447534-111447534 0
36 COSM6964890 SH2B3 salivary gland,major,carcinoma,NS c.241G>A p.D81N 12:111418386-111418386 0
37 COSM1159845 SF3B1 salivary gland,major,carcinoma,NS c.2324G>A p.R775Q 2:197401788-197401788 0
38 COSM5891771 SETD2 salivary gland,major,carcinoma,NS c.3994C>T p.P1332S 3:47084277-47084277 0
39 COSM5995773 SDHA salivary gland,major,carcinoma,NS c.724G>A p.G242R 5:228287-228287 0
40 COSM4991131 RPTOR salivary gland,major,carcinoma,NS c.3788C>T p.P1263L 17:80962556-80962556 0
41 COSM3451453 RPS6KA4 salivary gland,major,carcinoma,NS c.967C>T p.R323C 11:64365361-64365361 0
42 COSM6983822 ROS1 salivary gland,major,carcinoma,NS c.2878G>A p.G960R 6:117365676-117365676 0
43 COSM5610508 ROS1 salivary gland,major,carcinoma,NS c.5794G>A p.E1932K 6:117320014-117320014 0
44 COSM6983819 ROS1 salivary gland,major,carcinoma,NS c.5211A>T p.E1737D 6:117337209-117337209 0
45 COSM3726697 RNF43 salivary gland,major,carcinoma,NS c.434G>A p.R145Q 17:58363542-58363542 0
46 COSM6983815 RICTOR salivary gland,major,carcinoma,NS c.712C>T p.P238S 5:38981908-38981908 0
47 COSM1644939 RB1 salivary gland,major,carcinoma,NS c.1817A>G p.Y606C 13:48456206-48456206 0
48 COSM6913929 RASA1 salivary gland,major,carcinoma,NS c.2603+2T>A p.? 5:87379852-87379852 0
49 COSM6910894 RASA1 salivary gland,major,carcinoma,NS c.3026T>G p.L1009R 5:87389493-87389493 0
50 COSM6951920 RAD52 salivary gland,major,carcinoma,NS c.761C>G p.T254R 12:916448-916448 0

Expression for Salivary Gland Carcinoma

Search GEO for disease gene expression data for Salivary Gland Carcinoma.

Pathways for Salivary Gland Carcinoma

Pathways related to Salivary Gland Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 EGFR HGF KIT MAML2 MDM2 MET
2
Show member pathways
12.59 CDKN2A EGFR HGF KIT MET
3
Show member pathways
12.53 CDKN2A EGFR HGF MDM2 MET
4
Show member pathways
12.53 EGFR HGF KIT MDM2 MET
5
Show member pathways
12.42 EGFR HGF MDM2 MET
6 12.35 CDKN2A EGFR MDM2 MET
7 12.16 CDKN2A EGFR HGF KIT MDM2 MET
8 12.08 EGFR HGF MDM2 MET
9 11.81 CDKN2A EGFR MDM2
10 11.75 HGF ISL1 MET SOX2
11
Show member pathways
11.7 EGFR HGF MET
12 11.68 EGFR HGF MDM2 MET
13 11.59 CDKN2A EGFR MDM2
14 11.5 EGFR KIT MET
15 11.33 ISL1 KIT SOX2
16
Show member pathways
11.2 EGFR HGF MET
17 11.15 EGFR HGF MET
18 10.86 EGFR HGF MET
19 10.81 HGF MET
20 10.28 EGFR HGF MET

GO Terms for Salivary Gland Carcinoma

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 ALKBH3 CDKN2A CPSF4 CRTC1 CRTC3 ISL1
2 nucleus GO:0005634 9.5 ALKBH1 ALKBH3 CDKN2A CPSF4 CRTC1 CRTC3

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.88 ALKBH1 EGFR ISL1 SOX2
2 MAPK cascade GO:0000165 9.76 EGFR HGF KIT MET
3 negative regulation of apoptotic process GO:0043066 9.74 EGFR HGF MDM2
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.73 EGFR KIT MET
5 regulation of gene expression GO:0010468 9.73 ALKBH1 ISL1 MDM2 SOX2
6 liver development GO:0001889 9.7 EGFR HGF MET
7 positive regulation of protein kinase B signaling GO:0051897 9.62 EGFR HGF KIT MET
8 endocardial cushion morphogenesis GO:0003203 9.59 ISL1 MDM2
9 positive regulation of CREB transcription factor activity GO:0032793 9.58 CRTC1 CRTC3
10 hepatocyte growth factor receptor signaling pathway GO:0048012 9.55 HGF MET
11 tongue development GO:0043586 9.54 EGFR KIT
12 peptidyl-tyrosine phosphorylation GO:0018108 9.54 EGFR KIT MET
13 DNA dealkylation involved in DNA repair GO:0006307 9.51 ALKBH1 ALKBH3
14 locomotor rhythm GO:0045475 9.49 MC3R MTA1
15 somatic stem cell division GO:0048103 9.48 CDKN2A KIT
16 positive chemotaxis GO:0050918 9.43 ALKBH1 HGF MET
17 amyloid fibril formation GO:1990000 9.4 CDKN2A MDM2
18 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 CDKN2A CRTC1 CRTC3 EGFR HGF ISL1
19 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 HGF MET
20 positive regulation of MAPK cascade GO:0043410 8.96 KIT SOX2

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 9.16 CRTC1 CRTC3
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KIT MET
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 8.96 ALKBH1
4 protein tyrosine kinase activity GO:0004713 8.8 EGFR KIT MET

Sources for Salivary Gland Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....